


Using Molecular Structure to Design a Pan-specific Schistosomiasis Drug


Alexander B. Taylor¹, Xiaohang Cao¹, Stacey R. Stahl¹, Stephen P. Holloway¹, Timothy J.C. Anderson², Stanton F. McHardy³, Philip T. LoVerde¹ and P. John Hart¹

¹The University of Texas Health Science Center at San Antonio, ²Texas Biomedical Research Institute and ³The University of Texas at San Antonio

The Problem: Schistosomiasis

Schistosomes, commonly known as the blood fluke, infect an estimated 200 million people worldwide in 76 countries. The parasite is acquired from an intermediate freshwater snail host found mainly in Asia, Africa, and South America. Schistosomiasis, the chronic illness resulting from schistosome infection, is classified by the World Health Organization as a neglected tropical disease. Of the three main human blood fluke species, Schistosoma mansoni and S. haematobium together account for >99% of schistosomiasis cases worldwide with S. japonicum causing the remainder. Only one drug, praziquantel, is used to treat schistosomiasis worldwide and emerging resistance underscores the need for an alternative drug. Oxamniquine (OXA) is an earlier generation drug used until the 1990s that was effective against S. mansoni only. Our goal is to develop an oxamniquine derivative drug that is effective against all three human schistosome parasites.





Collaborators:

- Phil LoVerde, Parasitology, University of Texas Health Science Center
- Tim Anderson, Genetics, Texas Biomedical Research Institute
- Stan McHardy, Medicinal Chemistry, University of Texas at San Antonio Center for Innovation in Drug Discovery
- John Hart, Structural Biology, University of Texas Health Science Center X-ray Crystallography Core Laboratory

